The Outcomes of Hip and Knee Fungal Periprosthetic Joint Infections: A Retrospective Cohort Study

被引:4
|
作者
McCulloch, Robert A. [1 ]
Palmer, Antony J. [2 ]
Donaldson, James [1 ]
Kendrick, Benjamin J. [2 ]
Miles, Jonathan [1 ]
Taylor, Adrian [2 ]
机构
[1] Royal Natl Orthopaed Hosp, Brockley Hill, Stanmore HA7 4LP, Middx, England
[2] Nuffield Orthopaed Ctr, Oxford, England
来源
JOURNAL OF ARTHROPLASTY | 2023年 / 38卷 / 10期
关键词
fungal; periprosthetic joint infection; hip and knee arthroplasty; revision arthroplasty; polymicrobial infection; CANDIDA-ALBICANS BIOFILMS; SINGLE-STAGE REVISION; ANTIFUNGAL AGENTS; RISK-FACTORS; SUCCESS;
D O I
10.1016/j.arth.2023.05.005
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Background: Fungal infections are a rare cause of periprosthetic joint infection (PJI), identified in 1% of all of these cases. Outcomes are not well-established due to small cohort sizes in the published literature. The aims of this study were to establish the patient demographics and infection-free survival of patients presenting to 2 high-volume revision arthroplasty centers who had fungal infection of either a hip or knee arthroplasty. We sought to identify risk factors for poor outcomes. Methods: A retrospective analysis was performed of patients at 2 high-volume revision arthroplasty centers who had confirmed fungal PJI of the total hip arthroplasty (THA) and total knee arthroplasty (TKA). Consecutive patients treated between 2010 and 2019 were included. Patient outcomes were classified as infection eradication or persistence. A total of 67 patients who had 69 fungal PJI cases were identified. There were 47 cases involving the knee and 22 of the hip. Mean age at presentation was 68 years (THA mean 67, range 46 to 86) (TKA mean 69, range, 45 to 88). A history of sinus or open wound was present in 60 cases (89%) (THA 21 cases, TKA 39 cases). The median number of operations prior to the procedure at which fungal PJI was identified was 4 (range, 0 to 9), THA 5 (range, 3 to 9), and TKA 3 (range, 0 to 9). Results: At a mean follow-up 34 months (range, 2 to 121), remission rates were 11 of 24 (45%) and 22 of 45 (49%) for hip and knee, respectively. There were 7 TKA (16%) and 1 THA cases (4%) that failed treatment resulting in amputations. During the study period, 7 THA and 6 TKA patients had died. Two deaths were directly attributable to PJI. Patient outcome was not associated with the number of prior procedures, patient comorbidities, or organisms. Conclusion: Eradication of fungal PJI is achieved in less than half of patients, and outcomes are comparable for TKA and THA. The majority of patients who have fungal PJI present with an open wound or sinus. No factors were identified that increase the risk of persistent infection. Patients who have fungal PJI should be informed of the poor outcomes. Crown Copyright (c) 2023 Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
引用
收藏
页码:2183 / +
页数:6
相关论文
共 50 条
  • [31] Outcome of hip and knee periprosthetic joint infections caused by pathogens resistant to biofilm-active antibiotics: results from a prospective cohort study
    Akguen, Doruk
    Perka, Carsten
    Trampuz, Andrej
    Renz, Nora
    ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY, 2018, 138 (05) : 635 - 642
  • [32] Outcome of hip and knee periprosthetic joint infections caused by pathogens resistant to biofilm-active antibiotics: results from a prospective cohort study
    Doruk Akgün
    Carsten Perka
    Andrej Trampuz
    Nora Renz
    Archives of Orthopaedic and Trauma Surgery, 2018, 138 : 635 - 642
  • [33] Clinical Outcome of Massive Endoprostheses Used for Managing Periprosthetic Joint Infections of the Hip and Knee
    Alvand, Abtin
    Grammatopoulos, George
    de Vos, Floris
    Scarborough, Matthew
    Kendrick, Ben
    Price, Andrew
    Gundle, Roger
    Whitwell, Duncan
    Jackson, William
    Taylor, Adrian
    Gibbons, Christopher L. M. H.
    JOURNAL OF ARTHROPLASTY, 2018, 33 (03): : 829 - 834
  • [34] Long Pentraxin 3 as a New Biomarker for Diagnosis of Hip and Knee Periprosthetic Joint Infections
    Loppini, Mattia
    Di Maio, Marco
    Avigni, Roberta
    Leone, Roberto
    Inforzato, Antonio
    Grappiolo, Guido
    Mantovani, Alberto
    Bottazzi, Barbara
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (03)
  • [35] EVALUATION OF BIOMARKERS IN PATIENTS WITH POTENTIAL PERIPROSTHETIC JOINT INFECTIONS AFTER HIP AND KNEE ARTHROPLASTY
    Thudium, Christian S.
    Frederiksen, Peder
    Satriano, Letizia
    Karsdal, Morten
    Bay-Jensen, Anne C.
    Rasmussen, Sten
    OSTEOARTHRITIS AND CARTILAGE, 2024, 32 : S121 - S122
  • [36] Treatment algorithm for periprosthetic infections of the knee joint
    Luering, C.
    Lemmen, S. W.
    Quack, V.
    Beckmann, J.
    Tingart, M.
    Rath, B.
    ORTHOPADE, 2012, 41 (01): : 20 - 25
  • [37] Efficacy of a Novel Intraoperative Surgical Irrigant in Preventing Periprosthetic Joint Infections in Primary Knee, Hip, and Shoulder Arthroplasties: A Retrospective Analysis
    Williams, Marshall
    Harris, Robert M.
    ORTHOPAEDIC SURGERY, 2024, 16 (06) : 1277 - 1283
  • [38] Two-Stage Treatment Protocol of Fungal Periprosthetic Hip and Knee Joint Infections: the Clinical Experience from a Single Center Experience
    Xu, J.
    Sun, W.
    Wang, Y.
    Jiang, H.
    Ding, H.
    Cheng, Q.
    Bao, N.
    Meng, J.
    ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA, 2024, 91 (01) : 52 - 56
  • [39] Fungal periprosthetic joint infection of the hip: a systematic review
    Schoof, Benjamin
    Jakobs, Oliver
    Schmidl, Stefan
    Klatte, Till Orla
    Frommelt, Lars
    Gehrke, Thorsten
    Gebauer, Matthias
    ORTHOPEDIC REVIEWS, 2015, 7 (01) : 18 - 22
  • [40] Effect of Multiantibiotic-Loaded Bone Cement on the Treatment of Periprosthetic Joint Infections of Hip and Knee Arthroplasties-A Single-Center Retrospective Study
    Blersch, Benedikt Paul
    Sax, Florian Hubert
    Mederake, Moritz
    Benda, Sebastian
    Schuster, Philipp
    Fink, Bernd
    ANTIBIOTICS-BASEL, 2024, 13 (06):